<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02557451</url>
  </required_header>
  <id_info>
    <org_study_id>BRON PHRC I 2013</org_study_id>
    <nct_id>NCT02557451</nct_id>
  </id_info>
  <brief_title>Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents and Age Related Macular Degeneration Complications</brief_title>
  <acronym>STAR</acronym>
  <official_title>Subretinal Haematoma in AMD: Randomized Controlled Study of 2 Therapeutic Approaches in the Antiangiogenic Era</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <brief_summary>
    <textblock>
      AMD is a disease of the central retina, a zone that enables fine detail activities (reading,&#xD;
      detail…). This central zone of the retina can be affected by a haemorrhagic complication when&#xD;
      small abnormal vessels suddenly start to bleed inside the retina. Several therapeutic&#xD;
      approaches are currently available even though they have never been truly compared. The study&#xD;
      will be proposed to patients who need to be treated for haemorrhage of the macula. A certain&#xD;
      number of factors will be evaluated to compare the 2 principal approaches currently used in&#xD;
      France: surgery followed by injections of an anti-angiogenic OR intravitreal injections of&#xD;
      gas followed by injections of anti-angiogenics. This is a multicentre, randomized controlled&#xD;
      trial to compare these 2 therapeutic approaches.&#xD;
&#xD;
      These diametrically opposed approaches have very different consequences for patients and in&#xD;
      terms of cost for society. The consequences for patients will be immediately measurable so as&#xD;
      to determine the best therapeutic approach in terms of functional recovery and the impact of&#xD;
      the disease on quality of life, while taking into account the risks inherent to these 2&#xD;
      treatments. The impact on quality of life of these 2 approaches as well as their consequences&#xD;
      - an important factor in this disease, which is a cause of sensory handicap - will provide&#xD;
      the ophthalmological community with essential information making it possible to validate one&#xD;
      or the other of these methods for the management of these haematomas.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 28, 2016</start_date>
  <primary_completion_date type="Actual">May 5, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity measured on the ETDRS scale</measure>
    <time_frame>Change from inclusion at 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity measured on the ETDRS scale</measure>
    <time_frame>At 1 month and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area of the scotoma presented by the patient according to the Amsler grid</measure>
    <time_frame>At 1 month, 3 months and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life using the VFQ-25 scale</measure>
    <time_frame>At 3 months and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of injections of an antiangiogenic at the end of the 6 months of treatment</measure>
    <time_frame>At 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with macular bleeding</measure>
    <time_frame>At 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area of hypoautofluorescence using the autofluorescence technique</measure>
    <time_frame>At 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications rate</measure>
    <time_frame>At 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Subretinal Haematoma Linked to AMD</condition>
  <arm_group>
    <arm_group_label>surgery + antiangiogenic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>surgery (vitrectomy - air - TPA) with injections of an antiangiogenic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intravitreal injection of gas/TPA + antiangiogenic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravitreal injection of gas - TPA with injections of an antiangiogenic</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <arm_group_label>surgery + antiangiogenic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intravitreal injections of gas</intervention_name>
    <arm_group_label>intravitreal injection of gas/TPA + antiangiogenic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>injections of an antiangiogenic</intervention_name>
    <arm_group_label>intravitreal injection of gas/TPA + antiangiogenic</arm_group_label>
    <arm_group_label>surgery + antiangiogenic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients presenting subretinal haematoma linked to AMD&#xD;
&#xD;
          -  Occurring at least14 days before the start of therapy&#xD;
&#xD;
          -  With the presence of a component overlying the pigmentary epithelium (PE) on the OCT&#xD;
&#xD;
          -  And a diameter greater than two pupillary diameters on the retinal photographs&#xD;
&#xD;
        Patients who have provided oral consent&#xD;
&#xD;
        Patients with National Health Insurance cover&#xD;
&#xD;
        Patients available for monthly follow-up&#xD;
&#xD;
        Patient having an effective contraception for the women old enough to procreate during the&#xD;
        treatment and during 6 months which follow his stop.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subretinal haematoma linked to a cause other than AMD (myopia, angioid streaks…)&#xD;
&#xD;
          -  History of subretinal haematoma on the same side&#xD;
&#xD;
          -  Cloudy humour making it impossible to photograph the fundus of the eye or carry out&#xD;
             angiography&#xD;
&#xD;
          -  Component of the haematoma exclusively underlying the pigmentry epithelium&#xD;
&#xD;
          -  Haemorrhage without lifting of the retina&#xD;
&#xD;
          -  Patients presenting an INR greater than 4, thus contra-indicating surgery&#xD;
&#xD;
          -  Patients requiring cataract surgery in the first 3 months of the study&#xD;
&#xD;
          -  Patients presenting a contra-indication relative to injection of the antiangiogenic&#xD;
             (History of AVC bleeding or unknown origin in the last 6 months or MI in the 3&#xD;
             preceding months)&#xD;
&#xD;
          -  Pregnant or breast-feeding woman (the patients do not have to breast-feed during at&#xD;
             least 6 months after the administration of the last dose of the antiangiogénique)&#xD;
&#xD;
          -  Contraindication in the use of ranibizumab: hypersensitivity in the active ingredient&#xD;
             or in one of the excipients, eye infection or périoculaire active or suspected,&#xD;
             inflammation intraoculaire active severe, treatments anti-VEGF systematic or eye&#xD;
             concomitant,&#xD;
&#xD;
          -  Contraindication in the use of bevacizumab: hypersensitivity in the active substance&#xD;
             or in one of the excipients, the hypersensitivity in the products of the ovarian cells&#xD;
             of Chinese hamster (CHO) or in other antibodies human or humanized recombinants, heavy&#xD;
             surgical operation dating less than 28 days, not totally healed surgical wound,&#xD;
             history of lung bleeding or hémoptysie&#xD;
&#xD;
          -  Contraindication in the use of alteplase: hypersensitivity in the active substance, in&#xD;
             the gentamicine (a residue of the present manufacturing process in the state of&#xD;
             tracks), or in one of the excipients. As all the thrombolytic agents, contraindication&#xD;
             in every case associated to a high hemorrhagic risk (current significant hemorrhagic&#xD;
             disorder or during the last six months, hemorrhagic known diathesis, concomitant&#xD;
             treatment by oral anticoagulants with effective dose, severe or potentially dangerous,&#xD;
             obvious or recent bleeding, histories or suspicion of intra-cranial bleeding,&#xD;
             suspicion of sub-arachnoid bleeding or history of sub-arachnoid bleeding bound to an&#xD;
             aneurysm, histories of severe lesion of the central nervous system (for example&#xD;
             néoplasie, aneurysm, surgical operation intracerebral or intrathecal), recent&#xD;
             traumatic external cardiac massage (less than 10 days), delivery, recent draining of a&#xD;
             vessel not accessible to the compression (for example draining of the subclavian or&#xD;
             jugular vein),severe uncontrolled high blood pressure, bacterial endocarditis,&#xD;
             pericarditis, acute pancreatitis, gastrointestinal ulcers documented during the last 3&#xD;
             months, esophageal varices, arterial aneurysm, arterial or venous deformations,&#xD;
             neoplasia increasing the hemorrhagic risk, severe hepatic disease, including hepatic&#xD;
             insufficiency, cirrhosis, portal hypertension (esophageal varicose veins) and&#xD;
             evolutionary hepatitis, surgical operation or important traumas during the last 3&#xD;
             months.&#xD;
&#xD;
          -  Contraindication in the use of acetazolamide: hypersensitivity in the acetazolamide or&#xD;
             in one of excipients, severe hepatic, renal or suprarenal inadequacies, intolerance in&#xD;
             sulphonamide, histories of renal colic, allergy in the wheat (other than the coeliac&#xD;
             disease).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>CHU de BESANCON</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de COLMAR</name>
      <address>
        <city>Colmar</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI de CRETEIL</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de DIJON</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de GRENOBLE</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCL - Hôpital de la Croix-Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR de METZ-THIONVILLE</name>
      <address>
        <city>Metz</city>
        <zip>57085</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de MULHOUSE</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de NEVERS</name>
      <address>
        <city>Nevers</city>
        <zip>58000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondation Ophtalmologique A. de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de REIMS</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Mathilde</name>
      <address>
        <city>Rouen</city>
        <zip>76100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHC de STRASBOURG</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de TOULOUSE - Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de NANCY</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 16, 2015</study_first_submitted>
  <study_first_submitted_qc>September 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2015</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiogenesis Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

